Engineered immune cells take aim at Hard-to-Treat solid tumors
NCT ID NCT05437315
First seen Jun 24, 2026
Summary
This clinical trial tests a new type of immunotherapy called bi-specific CAR-T cells, which are designed to recognize and attack two targets (GD2 and PSMA) on solid tumor cells. The study will enroll up to 60 patients whose tumors have not responded to standard treatments. The main goals are to check the safety of these cells and see if they can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bi-4SCAR GD2/PSMA T cells (a type of immune cell therapy)
What this could lead to
If successful, this could offer a new treatment option for patients with advanced solid tumors that express GD2 and PSMA, potentially shrinking tumors or slowing disease progression.
What could go wrong
This is an early-phase trial (phase 1/2) with only 60 participants, so results may not apply to all patients. CAR-T therapy can cause serious side effects like cytokine release syndrome or neurological issues.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.